Sexual Dysfunction News and Research

Latest Sexual Dysfunction News and Research

Consequences of female genital mutilation could be reduced by reconstructive surgery

Reconstructive surgery after female genital mutilation (FGM) appears to reduce pain and restore sexual pleasure in women, according to the first large prospective trial to assess long-term outcomes of a new surgical technique published Online First in The Lancet. Over the past 10 years, between 130 and 140 million women worldwide have been subject to FGM.

12 Jun 2012

BioSante to initiate two new LibiGel Phase III efficacy trials in FSD, HSDD

BioSante Pharmaceuticals, Inc., announced today that the Company plans to initiate two new LibiGel Phase III efficacy trials. This decision is based on an extensive analysis of previous efficacy data, consultation with key opinion leaders (KOLs) in female sexual dysfunction, testosterone therapy and placebo effects, as well as a meeting with the U.S. Food and Drug Administration (FDA).

11 Jun 2012

Ampio’s CRO completes Optina clinical trial for DME

Ampio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, whose lead drugs treat inflammatory diseases, including osteoarthritis and complications of Diabetes Mellitus such as diabetic macular edema (and others) announced today that it's CRO has completed analysis of the primary end point in the Optina clinical trial for DME conducted at St Michael Diabetes Hospital in Toronto Canada.

11 Jun 2012

Positive results from Auxilium’s XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line results from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

4 Jun 2012

Psoriasis linked to sexual dysfunction in men

Men with psoriasis are at an increased risk for sexual dysfunction, research suggests.

1 Jun 2012

JMC publishes results from Rexahn’s RX-3117 preclinical cancer study

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Journal of Medicinal Chemistry on the anti-tumor activity of its RX-3117 compound.

1 Jun 2012

Nouveau Life Pharmaceuticals launches new supplement for women with FSD

Nouveau Life Pharmaceuticals, Inc. announced today the release of the first product in the Company's New Life Naturals line of quality, all-natural dietary supplements.

31 May 2012

Dyspnea limits sexual activity among older patients with COPD

Troublesome dyspnea that limits sexual activity is common among older patients with COPD, according to a new study from Denmark.

21 May 2012

Menarini, Furiex enter license agreement to commercialize Priligy

Furiex Pharmaceuticals, Inc. and Menarini Group today announced that they have entered into a license agreement by which Furiex will license to Menarini rights to commercialize Priligy in Europe, most of Asia, Africa, Latin America and the Middle East.

15 May 2012

Rexahn submits Phase II protocol for Archexin clinical study for ovarian cancer

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol for the clinical study of Archexin as a treatment of ovarian cancer to the U.S. Food and Drug Administration (FDA).

8 May 2012

Rexahn obtains additional patent coverage for anti-cancer candidate RX-1792 in Japan

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued to the Company patent No. 4,934,432, entitled "Quinazoline Derivatives and Therapeutic Use Thereof."

30 Apr 2012

FDA approves VIVUS’ STENDRA for treatment of erectile dysfunction

VIVUS, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved STENDRA (avanafil) tablets for the treatment of erectile dysfunction (ED), marking the first new prescription agent approved in nearly a decade for the condition that afflicts as many as 30 million men in the U.S.

30 Apr 2012

Enrollment complete for Ampio's multiple indication diagnostic clinical trials

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), announced today that it has completed enrollment of patients for its multiple indication diagnostic clinical trials.

12 Apr 2012

New 4th Edition of Practical Neurology for clinicians, residents and fellows

The new 4th Edition of Practical Neurology, the respected "real-life" guide to diagnosing and managing neurologic disorders, has been completely rewritten to known neurologist and chair of the Department of Neurology of Loyola University Chicago Stritch School of Medicine.

11 Apr 2012

Oxytocin may offer hope for male sexual dysfunction

The hormone oxytocin that is also called the “love hormone” since it plays a role in the bond between a mother and baby may also improve sexual function - at least in men with Asperger’s syndrome - according to a published case report.

10 Apr 2012

Ampio submits pre-IND package on Zertane to FDA

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, announced today that it submitted to the FDA a pre IND package on Zertane, its on-demand premature ejaculation drug, for a meeting and discussion on the approval path under the 505(b) 2 regulation/registration requirement in the US.

9 Apr 2012

Majority of female kidney failure patients on dialysis may experience sexual problems

The vast majority of female kidney failure patients on dialysis may experience sexual problems, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). Additional studies are needed to understand how sexual dysfunction affects dialysis patients' quality of life and psychological wellbeing.

6 Apr 2012

UCB receives FDA approval for Neupro to treat idiopathic Parkinson's, RLS

UCB announced today that the U.S. Food and Drug Administration (FDA) approved Neupro (Rotigotine Transdermal System) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson's disease (PD) and as a treatment for moderate-to-severe primary Restless Legs Syndrome.

3 Apr 2012

Ampio, Australian TGA reach agreement over Zertane submission plan

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, announced today that it reached agreement with the Therapeutic Goods Administration, Canberra, Australia, on a plan of drug manufacture and quality control for Zertane and the overall plan for the preparation of Common Technical Documents for the draft registration submission expected to be filed in June 2012.

2 Apr 2012

New pre-clinical data on Rexahn's RX-3117 study to be presented at AACR meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present new pre-clinical data on its oncology compound RX-3117 during a poster session at the American Association for Cancer Research (AACR) 103rd Annual Meeting being held in Chicago, Illinois, March 31 - April 4, 2012, at the McCormick Place Convention Center.

28 Mar 2012